about
Inhibition of Natural Killer Cells through Engagement of CD81 by the Major Hepatitis C Virus Envelope ProteinDisease-promoting effects of type I interferons in viral, bacterial, and coinfectionsType I interferons in infectious diseaseCombination adjuvants for the induction of potent, long-lasting antibody and T-cell responses to influenza vaccine in mice.Adjuvant is necessary for a robust immune response to a single dose of H1N1 pandemic flu vaccine in mice.Pathogenic potential of interferon αβ in acute influenza infectionThemis2 is not required for B cell development, activation, and antibody responses.Type I and type III interferons drive redundant amplification loops to induce a transcriptional signature in influenza-infected airway epitheliaA serpin shapes the extracellular environment to prevent influenza A virus maturationAdjuvanticity of the oil-in-water emulsion MF59 is independent of Nlrp3 inflammasome but requires the adaptor protein MyD88TRAIL+ monocytes and monocyte-related cells cause lung damage and thereby increase susceptibility to influenza-Streptococcus pneumoniae coinfection.Interactions with multiple peptide ligands determine the fate of developing thymocytes.Vaccinology at the beginning of the 21st century.Safety of MF59 adjuvant.Toll-like receptor 2 dependent immunogenicity of glycoconjugate vaccines containing chemically derived zwitterionic polysaccharides.Influenza A virus impairs control of Mycobacterium tuberculosis coinfection through a type I interferon receptor-dependent pathway.Immunology of TLR-independent vaccine adjuvants.The transcription factor E4BP4 is not required for extramedullary pathways of NK cell development.Natural amines inhibit activation of human plasmacytoid dendritic cells through CXCR4 engagement.The transcription factor E4bp4/Nfil3 controls commitment to the NK lineage and directly regulates Eomes and Id2 expression.Contribution of cytokines to pathology and protection in virus infection.Guarding the frontiers: the biology of type III interferons.The aryl hydrocarbon receptor controls cyclin O to promote epithelial multiciliogenesis.Intranasal administration of CpG induces a rapid and transient cytokine response followed by dendritic and natural killer cell activation and recruitment in the mouse lung.Introduction of zwitterionic motifs into bacterial polysaccharides generates TLR2 agonists able to activate APCs.IFNλ is a potent anti-influenza therapeutic without the inflammatory side effects of IFNα treatment.In vitro positive selection of alpha beta TCR transgenic thymocytes by a conditionally immortalized cortical epithelial clone.Stop the executioners.Coligation of the hepatitis C virus receptor CD81 with CD28 primes naive T lymphocytes to acquire type 2 effector function.Hepatitis C virions subvert natural killer cell activation to generate a cytokine environment permissive for infection.T cell costimulation by the hepatitis C virus envelope protein E2 binding to CD81 is mediated by Lck.Human plasmacytoid dendritic cells are unresponsive to bacterial stimulation and require a novel type of cooperation with myeloid dendritic cells for maturation.Antibody affinity maturation and respiratory syncytial virus disease.Binding of the hepatitis C virus envelope protein E2 to CD81 provides a co-stimulatory signal for human T cells.MF59 emulsion is an effective delivery system for a synthetic TLR4 agonist (E6020).Defective Vav expression and impaired F-actin reorganization in a subset of patients with common variable immunodeficiency characterized by T-cell defects.The adjuvants aluminum hydroxide and MF59 induce monocyte and granulocyte chemoattractants and enhance monocyte differentiation toward dendritic cells.Multiple Levels of Control Determine How E4bp4/Nfil3 Regulates NK Cell Development.Susceptibility and resistance to antigen-induced apoptosis in the thymus of transgenic mice.Multiple sites of post-activation CD8+ T cell disposal.
P50
Q27485143-B199D100-596D-4138-B864-DCF87370DA8CQ28082841-40EBF855-7D92-41FA-81E8-9841F111FEA8Q28255842-0F9D5DDA-D3EE-4990-A13B-91CA9EF49ECAQ30366836-2C6C43DA-2AD0-43AF-B30C-C19ED4980562Q30383794-390676A4-8073-4280-9914-83274379D07DQ33663298-8652891B-DEE4-4D07-8CEB-BF8B95AFD6DFQ33849219-DB225430-B758-4C2F-A6F4-E6B2673F7091Q35053045-D9244017-1E60-48B5-AAC7-9B3DA647C2D6Q35083702-4B14F790-5425-4D8F-8A6D-7D7A093B30A3Q35090905-FC4D9317-FBE5-4A36-9901-EDEE706BE5DDQ36078577-FD6491F2-03D3-4A7A-A943-FCA24CF4FD1AQ36096780-68D01669-BD97-43C5-92FE-07677BE9CF02Q36159950-0DFA97EA-08D7-433D-A87F-1622BB75CFE3Q37156975-885D2856-85C2-46E0-9C23-29FBBCFB424EQ37389041-463430D3-06F8-47F4-AFE4-B38BF423898CQ37416249-FBCEC657-21F7-4B35-9A13-472A9694570BQ37506781-6E3A5869-43DB-45CC-8E76-32459F3300D9Q37627731-033F80B7-B65B-4D4F-86EE-BA894875C239Q37642643-0EB92B8A-28A4-4D47-8418-7207DF083B2EQ37689403-D2F25B97-7B86-4236-BEA0-456A9156182EQ37996184-395A4568-6C87-4CAE-AA30-115F2D7A3B5DQ38550956-03852F30-8ADE-4D0F-86A2-4B06B42FF0DCQ39460723-5D8D1262-CDC8-47CB-A3FC-6D1529455D15Q39717410-C86EF6B3-02CC-41EE-B0D6-2513836CB8B6Q40041053-7710B0D3-6902-4EA3-B74F-90B621E0038BQ40577440-56B3A0AB-6412-4A04-89B2-884BCCC68A9FQ41123801-568F5AB3-B0F3-435B-87DC-EB612D7FE713Q41592636-C9132C4B-3B3D-4CAD-B039-E18E88394CD6Q42979305-A9E2255B-9E11-40CC-881D-60A59E20D4A9Q42993633-954C6080-6DAA-484D-A323-E4CE798A5D0BQ43049206-50196906-19BA-4F5D-8802-A29BDA2623FEQ44667863-ABFE107A-C27E-4CC5-A271-3381FB63E3BAQ45383013-3527DE34-4E50-42B4-980C-2D77088763E7Q45738814-2262C0F0-0FBA-4FEF-A61F-6969FAB5A6A4Q46102734-6AB8315D-6FCF-433C-8C25-03285429E99EQ46427725-E288BB21-597C-49AE-A20D-065237BA7CEFQ46662919-D31FEA38-C2C1-40F5-B889-18D09C61BDE0Q47193093-B1DB09BA-B2E0-4D80-87DC-A95D898FA3ECQ48032387-075CCB22-C937-4459-B0C2-4AA49A147E5AQ48787238-19495371-6846-4E58-AC30-EBE7218D1F38
P50
description
hulumtues
@sq
onderzoeker
@nl
researcher
@en
հետազոտող
@hy
name
Andreas Wack
@ast
Andreas Wack
@en
Andreas Wack
@es
Andreas Wack
@nl
type
label
Andreas Wack
@ast
Andreas Wack
@en
Andreas Wack
@es
Andreas Wack
@nl
prefLabel
Andreas Wack
@ast
Andreas Wack
@en
Andreas Wack
@es
Andreas Wack
@nl
P106
P21
P31
P496
0000-0001-5226-2991